These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20539081)

  • 1. Economic modeling of HIV treatments.
    Simpson KN
    Curr Opin HIV AIDS; 2010 May; 5(3):242-8. PubMed ID: 20539081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macroeconomic impact of HIV: the need for better modelling.
    Lamontagne E; Haacker M; Ventelou B; Greener R
    Curr Opin HIV AIDS; 2010 May; 5(3):249-54. PubMed ID: 20539082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between economic evaluations and HIV and AIDS treatment policies.
    Taleski SJ; Ahmed K; Whiteside A
    Curr Opin HIV AIDS; 2010 May; 5(3):204-9. PubMed ID: 20539075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV/AIDS care and treatment in sub-Saharan Africa.
    Kassaye SG; Katzenstein D
    AIDS Rev; 2003; 5(4):195-204. PubMed ID: 15011998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research as a path to wide-scale implementation of antiretroviral therapy in Africa.
    Sanne I; van der Horst C
    J HIV Ther; 2004 Sep; 9(3):65-8. PubMed ID: 15534564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equity and efficiency in scaling up access to HIV-related interventions in resource-limited settings.
    Cleary S
    Curr Opin HIV AIDS; 2010 May; 5(3):210-4. PubMed ID: 20539076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined antiviral treatment in HIV infection. Is it value for money?
    Davies D; Carne C; Camilleri-Ferrante C
    Public Health; 1999 Nov; 113(6):315-7. PubMed ID: 10637527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to optimize HIV treatment outcomes in resource-limited settings.
    Nakanjako D; Colebunders R; Coutinho AG; Kamya MR
    AIDS Rev; 2009; 11(4):179-89. PubMed ID: 19940945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical models and health economic aspects of microbicides.
    Wilson DP; Coplan PM
    Curr Opin HIV AIDS; 2008 Sep; 3(5):587-92. PubMed ID: 19373026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.
    Bennett DE
    Curr Opin Infect Dis; 2006 Dec; 19(6):607-14. PubMed ID: 17075338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
    Forsythe SS
    AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.